Michael Kassiou
Overview
Explore the profile of Michael Kassiou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
220
Citations
3981
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sokias R, Zhao A, Werry E, Montgomery A, Hibbs D, Sullivan M, et al.
RSC Med Chem
. 2025 Mar;
PMID: 40060999
The translocator protein (TSPO) is an 18 kDa protein on the outer mitochondrial membrane. It has gained significant interest in recent years for its potential as a therapeutic target and...
2.
Beaino W, Jm Kooijman E, Werry E, Vellinga R, Van den Hoek J, Sohler G, et al.
Eur J Nucl Med Mol Imaging
. 2025 Feb;
PMID: 39907797
Purpose: The translocator protein 18 kDa (TSPO) is a widely used marker for imaging neuroinflammation via Positron Emission Tomography (PET). However, the vast majority of reported TSPO PET tracers display...
3.
Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumaki E, Nylund M, et al.
EJNMMI Res
. 2024 Dec;
14(1):123.
PMID: 39636350
Background: PET imaging of activated microglia has improved our understanding of the pathology behind disability progression in MS, and pro-inflammatory microglia at 'smoldering' lesion rims have been implicated as drivers...
4.
Cumbers G, Harvey-Latham E, Kassiou M, Werry E, Danon J
Semin Nucl Med
. 2024 Oct;
54(6):856-874.
PMID: 39477764
The translocator protein (TSPO) is a biomarker for imaging neuroinflammation via Positron Emission Tomography (PET) across a broad range of CNS conditions. Most clinically used PET ligands targeting TSPO have...
5.
Dhar K, Townsend B, Montgomery A, Danon J, Pagan J, Kassiou M
Trends Pharmacol Sci
. 2024 Oct;
45(11):982-996.
PMID: 39419743
Mitophagy, the selective degradation of mitochondria, is impaired in many neurodegenerative diseases (NDs), resulting in an accumulation of dysfunctional mitochondria and neuronal damage. Although enhancing mitophagy shows promise as a...
6.
Rubin L, Maki P, Du Y, Sweeney S, OToole R, Nam H, et al.
AIDS
. 2024 Oct;
39(2):133-142.
PMID: 39405127
Objectives: Virally suppressed people with HIV (VS-PWH) show heterogeneity in patterns of cognitive dysfunction. To better understand the relationship between the neuroimmune response and cognition, we used PET to image...
7.
John Hamilton A, Lane S, Werry E, Suri A, Bailey A, Merce C, et al.
ChemMedChem
. 2024 Jun;
19(19):e202400098.
PMID: 38923350
Antitumour properties of some cannabinoids (CB) have been reported in the literature as early as 1970s, however there is no clear consensus to date on the exact mechanisms leading to...
8.
Garrett T, Gilchrist J, McKenzie A, Larik F, Danon J, Werry E, et al.
ChemMedChem
. 2024 May;
19(17):e202400163.
PMID: 38782733
Despite their acknowledged significance in the inflammatory signalling cascade across a range of disease states, P2X7R antagonists have not yet proven to be effective in clinical trials. In this study,...
9.
Giladi M, Montgomery A, Kassiou M, Danon J
Biochimie
. 2024 May;
224:41-50.
PMID: 38782353
The translocator protein 18 kDa (TSPO) is an evolutionarily conserved mitochondrial transmembrane protein implicated in various neuropathologies and inflammatory conditions, making it a longstanding diagnostic and therapeutic target of interest....
10.
Sparkes E, Maloney C, Markham J, Dane C, Boyd R, Gilchrist J, et al.
ACS Chem Neurosci
. 2024 May;
15(11):2160-2181.
PMID: 38766866
Synthetic cannabinoid receptor agonists (SCRAs) are a growing class of new psychoactive substances (NPS) commonly derived from an -alkylated indole, indazole, or 7-azaindole scaffold. Diversification of this core (at the...